nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—MTOR—Downstream signal transduction—ERBB4—gallbladder cancer	0.00536	0.00541	CbGpPWpGaD
Everolimus—MTOR—Leptin signaling pathway—ERBB2—gallbladder cancer	0.00536	0.0054	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—ERBB4—gallbladder cancer	0.00534	0.00538	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—ERBB4—gallbladder cancer	0.00531	0.00535	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—ERBB4—gallbladder cancer	0.00528	0.00533	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—ERBB4—gallbladder cancer	0.00521	0.00525	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—ERBB3—gallbladder cancer	0.00516	0.0052	CbGpPWpGaD
Everolimus—MTOR—CXCR3-mediated signaling events—HRAS—gallbladder cancer	0.00514	0.00518	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—ERBB4—gallbladder cancer	0.00497	0.00501	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—ERBB4—gallbladder cancer	0.00497	0.00501	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—ERBB4—gallbladder cancer	0.00497	0.00501	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—ERBB3—gallbladder cancer	0.00493	0.00497	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—ERBB4—gallbladder cancer	0.00493	0.00497	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—ERBB4—gallbladder cancer	0.00488	0.00492	CbGpPWpGaD
Everolimus—MTOR—LKB1 signaling events—TP53—gallbladder cancer	0.00486	0.0049	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—ERBB4—gallbladder cancer	0.00486	0.0049	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—ERBB3—gallbladder cancer	0.00485	0.00489	CbGpPWpGaD
Everolimus—MTOR—ErbB2/ErbB3 signaling events—HRAS—gallbladder cancer	0.00483	0.00487	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—EGFR—gallbladder cancer	0.00483	0.00487	CbGpPWpGaD
Everolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—ERBB2—gallbladder cancer	0.0048	0.00484	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—BCL2—gallbladder cancer	0.00464	0.00468	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—ERBB3—gallbladder cancer	0.00464	0.00467	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—ERBB3—gallbladder cancer	0.00461	0.00465	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—ERBB4—gallbladder cancer	0.0046	0.00464	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—EGFR—gallbladder cancer	0.00459	0.00463	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—ERBB3—gallbladder cancer	0.00459	0.00463	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—ERBB3—gallbladder cancer	0.00457	0.00461	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—KRAS—gallbladder cancer	0.00456	0.0046	CbGpPWpGaD
Everolimus—MTOR—mTOR signaling pathway—NRAS—gallbladder cancer	0.00451	0.00455	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—ERBB2—gallbladder cancer	0.00451	0.00455	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—ERBB3—gallbladder cancer	0.0045	0.00454	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—ERBB4—gallbladder cancer	0.0044	0.00444	CbGpPWpGaD
Everolimus—MTOR—PI-3K cascade—ERBB2—gallbladder cancer	0.00432	0.00436	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—ERBB3—gallbladder cancer	0.0043	0.00433	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—ERBB3—gallbladder cancer	0.0043	0.00433	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—ERBB3—gallbladder cancer	0.0043	0.00433	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—ERBB3—gallbladder cancer	0.00426	0.00429	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—ERBB3—gallbladder cancer	0.00422	0.00426	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—ERBB2—gallbladder cancer	0.00422	0.00426	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—BCL2—gallbladder cancer	0.00421	0.00425	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—ERBB3—gallbladder cancer	0.0042	0.00424	CbGpPWpGaD
Everolimus—MTOR—GAB1 signalosome—ERBB2—gallbladder cancer	0.00419	0.00422	CbGpPWpGaD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—ERBB2—gallbladder cancer	0.00409	0.00413	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—TP53—gallbladder cancer	0.00405	0.00409	CbGpPWpGaD
Everolimus—MTOR—Regulation of Telomerase—EGFR—gallbladder cancer	0.00402	0.00405	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—ERBB3—gallbladder cancer	0.00398	0.00401	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—KRAS—gallbladder cancer	0.00393	0.00397	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—KEAP1—gallbladder cancer	0.0039	0.00394	CbGpPWpGaD
Everolimus—MTOR—mTOR signaling pathway—KRAS—gallbladder cancer	0.00388	0.00392	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—HRAS—gallbladder cancer	0.00388	0.00391	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—TP53—gallbladder cancer	0.00386	0.00389	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—ERBB3—gallbladder cancer	0.00381	0.00384	CbGpPWpGaD
Everolimus—MTOR—IRS-mediated signalling—NRAS—gallbladder cancer	0.00369	0.00372	CbGpPWpGaD
Everolimus—MTOR—IRS-related events—NRAS—gallbladder cancer	0.00359	0.00362	CbGpPWpGaD
Everolimus—MTOR—IRS-related events triggered by IGF1R—NRAS—gallbladder cancer	0.00355	0.00358	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—TP53—gallbladder cancer	0.0035	0.00352	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—NRAS—gallbladder cancer	0.00346	0.00349	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—NRAS—gallbladder cancer	0.00346	0.00349	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—ERBB4—gallbladder cancer	0.00339	0.00341	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—HRAS—gallbladder cancer	0.00334	0.00337	CbGpPWpGaD
Everolimus—MTOR—AMPK Signaling—TP53—gallbladder cancer	0.00333	0.00336	CbGpPWpGaD
Everolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—EGFR—gallbladder cancer	0.00333	0.00336	CbGpPWpGaD
Everolimus—MTOR—mTOR signaling pathway—HRAS—gallbladder cancer	0.0033	0.00333	CbGpPWpGaD
Everolimus—MTOR—TSH signaling pathway—HRAS—gallbladder cancer	0.0033	0.00333	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—ERBB2—gallbladder cancer	0.00323	0.00326	CbGpPWpGaD
Everolimus—MTOR—IRS-mediated signalling—KRAS—gallbladder cancer	0.00317	0.0032	CbGpPWpGaD
Everolimus—MTOR—CDC42 signaling events—HRAS—gallbladder cancer	0.00315	0.00318	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—BCL2—gallbladder cancer	0.00315	0.00318	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—EGFR—gallbladder cancer	0.00312	0.00315	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—NRAS—gallbladder cancer	0.00311	0.00314	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—ERBB2—gallbladder cancer	0.00309	0.00312	CbGpPWpGaD
Everolimus—MTOR—IRS-related events—KRAS—gallbladder cancer	0.00309	0.00311	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—NRAS—gallbladder cancer	0.00307	0.00309	CbGpPWpGaD
Everolimus—MTOR—IRS-related events triggered by IGF1R—KRAS—gallbladder cancer	0.00306	0.00308	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—ERBB2—gallbladder cancer	0.00304	0.00307	CbGpPWpGaD
Everolimus—MTOR—PI-3K cascade—EGFR—gallbladder cancer	0.003	0.00302	CbGpPWpGaD
Everolimus—MTOR—Leptin signaling pathway—HRAS—gallbladder cancer	0.00298	0.00301	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—KRAS—gallbladder cancer	0.00298	0.003	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—KRAS—gallbladder cancer	0.00298	0.003	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—KRAS—gallbladder cancer	0.00295	0.00298	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—ERBB3—gallbladder cancer	0.00293	0.00295	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—EGFR—gallbladder cancer	0.00293	0.00295	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—ERBB2—gallbladder cancer	0.00291	0.00293	CbGpPWpGaD
Everolimus—MTOR—GAB1 signalosome—EGFR—gallbladder cancer	0.0029	0.00293	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—NRAS—gallbladder cancer	0.00289	0.00292	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—ERBB2—gallbladder cancer	0.00289	0.00292	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—ERBB2—gallbladder cancer	0.00289	0.00292	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—ERBB2—gallbladder cancer	0.00288	0.0029	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—NRAS—gallbladder cancer	0.00287	0.0029	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—ERBB2—gallbladder cancer	0.00286	0.00289	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—EGFR—gallbladder cancer	0.00284	0.00286	CbGpPWpGaD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—gallbladder cancer	0.00284	0.00286	CbGpPWpGaD
Everolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—HRAS—gallbladder cancer	0.00283	0.00285	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—ERBB2—gallbladder cancer	0.00282	0.00285	CbGpPWpGaD
Everolimus—MTOR—IRS-mediated signalling—HRAS—gallbladder cancer	0.0027	0.00272	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—ERBB2—gallbladder cancer	0.00269	0.00272	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—ERBB2—gallbladder cancer	0.00269	0.00272	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—ERBB2—gallbladder cancer	0.00269	0.00272	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—KRAS—gallbladder cancer	0.00268	0.0027	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—ERBB2—gallbladder cancer	0.00267	0.00269	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—ERBB2—gallbladder cancer	0.00265	0.00267	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—KRAS—gallbladder cancer	0.00264	0.00266	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—ERBB2—gallbladder cancer	0.00264	0.00266	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—gallbladder cancer	0.00262	0.00265	CbGpPWpGaD
Everolimus—MTOR—IRS-related events—HRAS—gallbladder cancer	0.00262	0.00264	CbGpPWpGaD
Everolimus—MTOR—IRS-related events triggered by IGF1R—HRAS—gallbladder cancer	0.0026	0.00262	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—HRAS—gallbladder cancer	0.00253	0.00255	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—HRAS—gallbladder cancer	0.00253	0.00255	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—ERBB2—gallbladder cancer	0.00249	0.00251	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—KRAS—gallbladder cancer	0.00249	0.00251	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—KRAS—gallbladder cancer	0.00247	0.00249	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—NRAS—gallbladder cancer	0.00246	0.00248	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—ERBB2—gallbladder cancer	0.00239	0.00241	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—TP53—gallbladder cancer	0.00238	0.0024	CbGpPWpGaD
Everolimus—MTOR—Immune System—KEAP1—gallbladder cancer	0.00237	0.00239	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—NRAS—gallbladder cancer	0.00235	0.00237	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—NRAS—gallbladder cancer	0.00232	0.00233	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—HRAS—gallbladder cancer	0.00228	0.0023	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—HRAS—gallbladder cancer	0.00228	0.0023	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—HRAS—gallbladder cancer	0.00224	0.00226	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—EGFR—gallbladder cancer	0.00224	0.00226	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—NRAS—gallbladder cancer	0.00221	0.00223	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—NRAS—gallbladder cancer	0.0022	0.00222	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—NRAS—gallbladder cancer	0.00219	0.00221	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—NRAS—gallbladder cancer	0.00218	0.0022	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NRAS—gallbladder cancer	0.00215	0.00217	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—EGFR—gallbladder cancer	0.00214	0.00216	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—gallbladder cancer	0.00212	0.00214	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—HRAS—gallbladder cancer	0.00212	0.00214	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—KRAS—gallbladder cancer	0.00212	0.00213	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—EGFR—gallbladder cancer	0.00211	0.00213	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—HRAS—gallbladder cancer	0.0021	0.00212	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—NRAS—gallbladder cancer	0.00205	0.00207	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—NRAS—gallbladder cancer	0.00205	0.00207	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NRAS—gallbladder cancer	0.00205	0.00207	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—NRAS—gallbladder cancer	0.00203	0.00205	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—KRAS—gallbladder cancer	0.00203	0.00204	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—EGFR—gallbladder cancer	0.00201	0.00203	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—NRAS—gallbladder cancer	0.00201	0.00203	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—EGFR—gallbladder cancer	0.002	0.00202	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—gallbladder cancer	0.002	0.00202	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—NRAS—gallbladder cancer	0.002	0.00202	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—KRAS—gallbladder cancer	0.002	0.00202	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—EGFR—gallbladder cancer	0.002	0.00201	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—KRAS—gallbladder cancer	0.00199	0.00201	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—EGFR—gallbladder cancer	0.00199	0.002	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—gallbladder cancer	0.00196	0.00197	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—ERBB4—gallbladder cancer	0.00193	0.00195	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—KRAS—gallbladder cancer	0.0019	0.00192	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—NRAS—gallbladder cancer	0.0019	0.00191	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—KRAS—gallbladder cancer	0.00189	0.00191	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—KRAS—gallbladder cancer	0.00189	0.00191	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—KRAS—gallbladder cancer	0.00188	0.0019	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—KRAS—gallbladder cancer	0.00188	0.00189	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—gallbladder cancer	0.00187	0.00188	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—EGFR—gallbladder cancer	0.00187	0.00188	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—EGFR—gallbladder cancer	0.00187	0.00188	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—ERBB4—gallbladder cancer	0.00185	0.00187	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—EGFR—gallbladder cancer	0.00185	0.00187	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KRAS—gallbladder cancer	0.00185	0.00186	CbGpPWpGaD
Everolimus—FKBP1A—Disease—ERBB4—gallbladder cancer	0.00185	0.00186	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—ERBB2—gallbladder cancer	0.00184	0.00185	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—EGFR—gallbladder cancer	0.00183	0.00185	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—EGFR—gallbladder cancer	0.00183	0.00184	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NRAS—gallbladder cancer	0.00182	0.00183	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—HRAS—gallbladder cancer	0.0018	0.00181	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—TP53—gallbladder cancer	0.00178	0.0018	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—HRAS—gallbladder cancer	0.00177	0.00178	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—KRAS—gallbladder cancer	0.00176	0.00178	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KRAS—gallbladder cancer	0.00176	0.00178	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—KRAS—gallbladder cancer	0.00176	0.00178	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—KRAS—gallbladder cancer	0.00175	0.00176	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—KRAS—gallbladder cancer	0.00173	0.00175	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—EGFR—gallbladder cancer	0.00173	0.00174	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—KRAS—gallbladder cancer	0.00173	0.00174	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—HRAS—gallbladder cancer	0.00172	0.00174	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—HRAS—gallbladder cancer	0.00169	0.00171	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—ERBB3—gallbladder cancer	0.00167	0.00168	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—gallbladder cancer	0.00165	0.00167	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—KRAS—gallbladder cancer	0.00163	0.00165	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—HRAS—gallbladder cancer	0.00163	0.00164	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—HRAS—gallbladder cancer	0.00162	0.00163	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—HRAS—gallbladder cancer	0.00161	0.00162	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—gallbladder cancer	0.00161	0.00162	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—ERBB3—gallbladder cancer	0.0016	0.00162	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—HRAS—gallbladder cancer	0.0016	0.00162	CbGpPWpGaD
Everolimus—FKBP1A—Disease—ERBB3—gallbladder cancer	0.0016	0.00161	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—HRAS—gallbladder cancer	0.00159	0.00161	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—gallbladder cancer	0.00157	0.00158	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—gallbladder cancer	0.00156	0.00158	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—HRAS—gallbladder cancer	0.0015	0.00151	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—HRAS—gallbladder cancer	0.0015	0.00151	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—gallbladder cancer	0.0015	0.00151	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—HRAS—gallbladder cancer	0.00149	0.0015	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—HRAS—gallbladder cancer	0.00147	0.00149	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—HRAS—gallbladder cancer	0.00147	0.00148	CbGpPWpGaD
Everolimus—MTOR—epithelium—gallbladder cancer	0.00145	0.177	CbGeAlD
Everolimus—MTOR—Signaling by NGF—NRAS—gallbladder cancer	0.0014	0.00141	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—HRAS—gallbladder cancer	0.00139	0.0014	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—gallbladder cancer	0.00133	0.00134	CbGpPWpGaD
Everolimus—FKBP1A—epithelium—gallbladder cancer	0.0013	0.159	CbGeAlD
Everolimus—FKBP1A—Signaling Pathways—ERBB4—gallbladder cancer	0.00129	0.0013	CbGpPWpGaD
Everolimus—MTOR—pancreas—gallbladder cancer	0.00129	0.157	CbGeAlD
Everolimus—MTOR—Signaling by NGF—EGFR—gallbladder cancer	0.00127	0.00128	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—KRAS—gallbladder cancer	0.0012	0.00121	CbGpPWpGaD
Everolimus—FKBP1A—pancreas—gallbladder cancer	0.00116	0.142	CbGeAlD
Everolimus—MTOR—Cellular responses to stress—TP53—gallbladder cancer	0.00114	0.00115	CbGpPWpGaD
Everolimus—MTOR—Immune System—ERBB4—gallbladder cancer	0.00112	0.00113	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ERBB3—gallbladder cancer	0.00112	0.00113	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—BCL2—gallbladder cancer	0.00108	0.00109	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—ERBB2—gallbladder cancer	0.00105	0.00106	CbGpPWpGaD
Everolimus—MTOR—Disease—ERBB4—gallbladder cancer	0.00104	0.00105	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—HRAS—gallbladder cancer	0.00102	0.00103	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—ERBB2—gallbladder cancer	0.00101	0.00101	CbGpPWpGaD
Everolimus—FKBP1A—Disease—ERBB2—gallbladder cancer	0.001	0.00101	CbGpPWpGaD
Everolimus—MTOR—Immune System—ERBB3—gallbladder cancer	0.000973	0.000981	CbGpPWpGaD
Everolimus—MTOR—Disease—ERBB3—gallbladder cancer	0.000898	0.000905	CbGpPWpGaD
Everolimus—MTOR—liver—gallbladder cancer	0.000822	0.1	CbGeAlD
Everolimus—MTOR—Innate Immune System—NRAS—gallbladder cancer	0.000797	0.000803	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—NRAS—gallbladder cancer	0.000765	0.000771	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NRAS—gallbladder cancer	0.000762	0.000768	CbGpPWpGaD
Everolimus—FKBP1A—liver—gallbladder cancer	0.000739	0.0901	CbGeAlD
Everolimus—MTOR—Signaling Pathways—ERBB4—gallbladder cancer	0.000727	0.000733	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—EGFR—gallbladder cancer	0.000726	0.000732	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ERBB2—gallbladder cancer	0.000701	0.000707	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—EGFR—gallbladder cancer	0.000697	0.000703	CbGpPWpGaD
Everolimus—FKBP1A—Disease—EGFR—gallbladder cancer	0.000694	0.0007	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—KRAS—gallbladder cancer	0.000686	0.000691	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—KRAS—gallbladder cancer	0.000658	0.000664	CbGpPWpGaD
Everolimus—FKBP1A—Disease—KRAS—gallbladder cancer	0.000656	0.000661	CbGpPWpGaD
Everolimus—MTOR—lymph node—gallbladder cancer	0.00063	0.0768	CbGeAlD
Everolimus—MTOR—Signaling Pathways—ERBB3—gallbladder cancer	0.000629	0.000634	CbGpPWpGaD
Everolimus—MTOR—Immune System—BCL2—gallbladder cancer	0.000628	0.000633	CbGpPWpGaD
Everolimus—MTOR—Immune System—ERBB2—gallbladder cancer	0.00061	0.000615	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—HRAS—gallbladder cancer	0.000583	0.000588	CbGpPWpGaD
Everolimus—FKBP1A—lymph node—gallbladder cancer	0.000567	0.0691	CbGeAlD
Everolimus—MTOR—Disease—ERBB2—gallbladder cancer	0.000563	0.000568	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—HRAS—gallbladder cancer	0.00056	0.000564	CbGpPWpGaD
Everolimus—FKBP1A—Disease—HRAS—gallbladder cancer	0.000557	0.000562	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NRAS—gallbladder cancer	0.000533	0.000538	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EGFR—gallbladder cancer	0.000486	0.00049	CbGpPWpGaD
Everolimus—MTOR—Immune System—NRAS—gallbladder cancer	0.000464	0.000468	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KRAS—gallbladder cancer	0.000459	0.000463	CbGpPWpGaD
Everolimus—MTOR—Disease—NRAS—gallbladder cancer	0.000428	0.000432	CbGpPWpGaD
Everolimus—MTOR—Immune System—EGFR—gallbladder cancer	0.000423	0.000426	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TP53—gallbladder cancer	0.000408	0.000411	CbGpPWpGaD
Everolimus—MTOR—Immune System—KRAS—gallbladder cancer	0.000399	0.000403	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ERBB2—gallbladder cancer	0.000394	0.000398	CbGpPWpGaD
Everolimus—MTOR—Disease—EGFR—gallbladder cancer	0.00039	0.000393	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HRAS—gallbladder cancer	0.00039	0.000393	CbGpPWpGaD
Everolimus—MTOR—Disease—KRAS—gallbladder cancer	0.000369	0.000372	CbGpPWpGaD
Everolimus—MTOR—Immune System—HRAS—gallbladder cancer	0.000339	0.000342	CbGpPWpGaD
Everolimus—MTOR—Disease—HRAS—gallbladder cancer	0.000313	0.000316	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NRAS—gallbladder cancer	0.0003	0.000302	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EGFR—gallbladder cancer	0.000273	0.000276	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KRAS—gallbladder cancer	0.000258	0.00026	CbGpPWpGaD
Everolimus—CYP3A4—liver—gallbladder cancer	0.000242	0.0294	CbGeAlD
Everolimus—MTOR—Signaling Pathways—TP53—gallbladder cancer	0.000229	0.000231	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HRAS—gallbladder cancer	0.000219	0.000221	CbGpPWpGaD
